Multiple Therapies for COVID-19

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Lisa Barrett

Stay on your current meds

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment. All hospitalized persons with moderate to severe COVID-19 disease that meet eligibility criteria will be offered participation.

Eligibility Criteria

This trial is for hospitalized adults with moderate to severe COVID-19, confirmed by a test. Participants must have lung issues or need oxygen support but can't join if they have certain liver problems, untreated TB, active hepatitis B/C, recent serious infections, are pregnant/breastfeeding, or have severe kidney disease.

Inclusion Criteria

I am 18 years old or older.

I have moderate to severe COVID-19 according to WHO standards.

My condition requires oxygen but not ICU-level care, or I need ICU care due to severe symptoms.

My potassium, magnesium, and calcium levels are normal before starting treatment.

I have lung issues, need oxygen, or am on a ventilator.

Treatment Details

The study tests Tocilizumab (blocks inflammation), Remdesivir (antiviral) alone or with Baricitinib (reduces immune response), alongside standard care. It aims to see how well these treatments work and their safety in different severity levels of COVID-19 patients.

5Treatment groups

Experimental Treatment

Active Control

Group I: TocilizumabExperimental Treatment1 Intervention

Severe, critical disease

Group II: Remdesivir + baricitinibExperimental Treatment1 Intervention

Moderate and severe, not critical disease

Group III: RemdesivirExperimental Treatment1 Intervention

Moderate and severe, not critical disease

Group IV: BaricitinibExperimental Treatment1 Intervention

Moderate and severe, not critical disease

Group V: Clinical standard of careActive Control1 Intervention